Find information on thousands of medical conditions and prescription drugs.

Mefloquine

Mefloquine is an orally administered antimalarial drug used as a prophylaxis against and treatment for malaria. It also goes by the trade name LariamTM (manufactured by Roche Pharmaceuticals) and chemical name mefloquine hydrochloride (forumulated with HCl). Mefloquine was developed in the 1970s at the Walter Reed Army Institute of Research in the U.S. as a chemical synthetic similar to quinine. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
Macrodantin
Maprotiline
Marcaine
Marezine
Marijuana
Marinol
Marplan
Matulane
Maxair
Maxalt
Maxolon
MDMA
Measurin
Mebendazole
Mebendazole
Meclofenoxate
Medrol
Mefenamic acid
Mefloquine
Melagatran
Melarsoprol
Meloxicam
Melphalan
Memantine
Metadate
Metamfetamine
Metamizole sodium
Metandienone
Metaxalone
Metenolone
Metformin
Methadone
Methamphetamine
Methaqualone
Metharbital
Methcathinone
Methenamine
Methionine
Methocarbamol
Methohexital
Methotrexate
Methotrexate
Methoxsalen
Methylcellulose
Methyldopa
Methylergometrine
Methylin
Methylphenidate
Methylphenobarbital
Methylprednisolone
Methyltestosterone
Methysergide
Metiamide
Metoclopramide
Metohexal
Metoprolol
Metrogel
Metronidazole
Metyrapone
Mobic
Moclobemide
Modafinil
Modicon
Monopril
Montelukast
Motrin
Moxidectin
Moxifloxacin
Moxonidine
MS Contin
Mucinex
Mucomyst
Mupirocin
Mupirocin
Muse
Mycitracin
Mycostatin
Myfortic
Mykacet
Mykinac
Myleran
Mylotarg
Mysoline
Phentermine
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Side-effects

Like many other drugs, mefloquine has adverse side-effects. It is known to cause severe depression, anxiety, paranoia, nightmares, insomnia, vestibular (balance) damage and central nervous system problems. For a complete list of adverse physical and psychological effects — including suicidal ideation — see the most recent product information. In 2002 the word "suicide" was added to the official product label, though proof of causation has not been established. Since 2003, the FDA has required that patients be screened before mefloquine is prescribed. Anyone taking antidepressants or with a history of psychiatric illness should not take mefloquine. The latest Consumer Medication Guide to Lariam has more complete information.

In the 1990s there were reports in the media that the drug may have played a role in the Somalia Affair, the misbehaviour of Canadian peacekeeping troops on duty in Somalia. There has been similar controversy since three murder-suicides involving Special Forces soldiers at Fort Bragg, N.C., in the summer of 2002. To date more than 19 cases of vestibular damage following the use of mefloquine have been diagnosed by military physicians. The same damage has been diagnosed among business travelers and tourists.

Neurological activity

In 2004, researchers found that mefloquine in adult mice blocks connexins called Cx36 and Cx50. Cx36 is found in the brain and Cx50 is located in the eye lens. Connexins in the brain are believed to play a role in movement, vision and memory.

Chirality and its implications

Mefloquine is a chiral molecule. It contains two asymmetric carbons, which means there are a total of four different enantiomers of the molecule. Mefloquine is currently manufactured and sold as a racemate of the (+/-) R*,S* enantiomers by Hoffman-LaRoche, a Swiss pharmaceutical company. According to some research, the (+) enantiomer is more effective in treating malaria, and the (-) enantiomer specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects. Some believe that it is irresponsible for a pharmaceutical company to sell mefloquine as a racemic mixture. It is not known whether mefloquine goes through stereoisomeric switching in vivo.

Advice to travelers

Mefloquine is one of the antimalarial drugs which the August 2005 issue of the CDC Travel Health Yellow Sheet advises travelers in areas with malaria risk — Africa, South America, the Indian subcontinent, Asia, and the South Pacific — to take.

There are virulent strains of malaria that are resistant to one or more anti-malarial drugs; for example, there are mefloquine-resistant strains in Thailand. Travelers are advised to compare current recommendations before selecting an antimalarial drug as the occurrence of drug-resistant strains changes.

Read more at Wikipedia.org


[List your site here Free!]


Blackwater fever in children, Burundi
From Emerging Infectious Diseases, 7/1/05 by Federico Gobbi

Blackwater fever is characterized by acute intravascular hemolysis with hemoglobinuria in patients with Plasmodium falciparum malaria. Its pathogenesis and management are still debated. Nine cases of this syndrome occurred in 2003 at Kiremba Hospital in Burundi in children receiving multiple quinine treatments.

**********

Blackwater fever (BWF) is a clinical entity well known only in long-term residents in Plasmodium falciparum-endemic areas who take quinine irregularly. This syndrome became less frequent when chloroquine was the drug of choice for malaria from 1950 until the 1990s (1). Glucose-6-phosphate dehydrogenase (G6PD) deficiency is also frequently associated with the syndrome; however, its role is not determinant, as BWF is frequently described in patients with normal erythrocyte G6PD levels who are receiving quinine for severe malaria (2). Isolated cases have also been described with other antimalarials, such as halofantrine and mefloquine, which belong to the amino-alcohol drug family (3 5).

The pathogenesis of BWF thus remains unclear (4,6,7). Its management changed with the introduction of artemisinin derivates but is still debated. White and other researchers (2,8) state that parenteral quinine can be stopped when artemisinin derivatives are available because they seem to be safe and well tolerated.

Clinical features defining BWF are well established (2,9). The syndrome is characterized by severe intravascular hemolysis and anemia producing dark urine in patients with severe malaria. Abdominal pain, jaundice, hepatosplenomegaly, vomiting, and renal failure (especially in adults) have also been reported.

As P. falciparum resistance to chloroquine developed, quinine was increasingly used in clinical practice for treating intermittent malaria infections. BWF seemed to reappear at the end of the 1990s, according to descriptions in several European clinics of imported diseases (3-5). It particularly affected European missionaries with years of previous residence in malarious areas. In fact, some of the classical definitions of the syndrome described it in expatriate populations only (9). Cases of BWF in autochthonous populations have recently been described in the literature from Southeast Asia (10) and in African children in Senegal (7). We describe a large number of BWF cases in the pediatric ward of a hospital in the Burundi highlands, where no case has been observed in the previous 10-year period (1992 2002).

The Study

Since January 1992, a hospital-based survey of malaria has been conducted at Kiremba Hospital in Ngozi Province. This 140-bed facility is located 1,540 m above sea level in the Burundi highlands; it serves a population of 75,000 (11).

For each case of malaria, laboratory data and clinical findings are recorded. Rising illness and death rates are being reported throughout Burundi, where P. falciparum accounts for most cases (12). According to the Kiremba Hospital registry, a 2-fold increase in admissions for malaria in the pediatric ward (children [less than or equal to] 14 years of age) was recorded from 1997 (658 cases) to 2002 (1,343 cases).

From February to December 2003, a period when 1,039 malaria patients were hospitalized, we observed 9 cases of severe intravascular hemolysis with dark urine in pediatric patients who had been treated with quinine. These children were all male with a mean age of 8.2 years (range 3-14 years). According to patients' health cards, all had been previously treated with quinine, either parenterally or orally according to Burundi's national policy for treating severe malaria (10 mg/kg 3x/day for 7 days). Clinical and laboratory data are presented in the Table.

When BWF occurred, quinine was stopped and artemether (3.2 mg/kg on day 1, then 1.6 mg/kg from day 2 to day 5), was administered intramuscularly in association with 3 days of corticosteroid therapy. All patients had severe anemia requiring blood transfusion according to hospital policy (hemoglobin <4.5 g/dL or <6 g/dL with accompanying dyspnea). Four patients needed 1 U of blood; 5 other patients needed >1 U. No deaths were recorded, and clinical outcome on discharge was satisfactory: thick smears were negative and hemoglobin levels had improved in all patients.

Conclusions

In Burundi, chloroquine was replaced by sulfadoxine-pyrimethamine (SP) alone as firstline treatment for uncomplicated malaria in 2001. However, the rapid development of resistance to SP brought back the use of oral quinine, a drug still available in health centers as well as in hospital settings. Since November 2003, artesunate and amodiaquine have replaced SP as firstline treatment in Burundi (13).

The result of the new treatment guidelines was a considerable reduction in the number of hospitalized malaria cases in 2004 (671 cases from January 1 to October 31, 2004). No cases of BWF were observed in this period. Despite changes in policy for the use of firstline antimalarial drugs, however, parenteral quinine continued to be the drug of choice for severe cases throughout this period.

All 9 patients with BWF seen in 2003 (with 1 exception) lived in the area served by Kiremba Hospital and were recorded during an 11-month period. This number represents an incidence of 11.5 cases/100.000 population/ year.

In reviewing recent literature, we found only 1 publication on BWF involving an African population (7). The study was carried out at the Dielmo village in Senegal, where 3 cases were detected in a 10-year prospective study in a small population (315 inhabitants). All 3 cases were in children who suffered several malaria attacks and were treated with oral or parenteral quinine, depending on the severity of the case. As a consequence, quinine was withdrawn as the drug of firstline therapy for uncomplicated cases of malaria. No more cases of BWF were recorded during the subsequent 6-year follow-up period.

In our study, patients were all boys admitted to the pediatric ward. No cases of oligoanuria were seen, which is not surprising in pediatric patients (14). At the onset of severe intravascular hemolysis, the blood smears of 2 children were negative for malaria; parasitemia was low in the others. These findings agree with the definition of BWF as being characterized by scanty or absent parasitemia (4,6,9). We were unable to determine G6PD levels in our patients, which is a major limitation of our study. However, in view of the overlap between malaria, quinine administration, and G6PD deficiency, the hemoglobinuria triggered by this deficiency should not be seen as a separate syndrome (10).

The management of our cases included 3 components: First, treatment with parenteral (intramuscular) artemether (3.2 mg/kg on day 1, then 1.6 mg/kg from days 2 to 5) after stopping quinine, according to recent trends in the literature (3-5). Artemisinin derivates have not been implicated in BWF episodes unless given in combination with mefloquine (8). Second, blood transfusion for severe anemia was performed according to the above described hospital policy. And finally, a short course of corticosteroid therapy was administered.

Our experience suggests the need to review the definition of BWF since the syndrome affects not only adult expatriates but also African children. All reported African children with cases of BWF had frequently received oral quinine therapy. African adults seem to be only occasionally affected. This finding suggests that BWF occurs in nonimmune persons or those who have not yet gained immunity. This statement is supported by the lack of cases in adults cured in the same hospital.

To reduce hemolysis, we treated BWF with corticosteroids, even though this step is not recommended by the World Health Organization. Our reasoning was that the phenomenon could be related to immune mechanisms in quinine-sensitized erythrocytes (14).

The influence of quinine seems to be an important factor in the pathogenesis of BWF. Other amino-alcohol drugs such as mefloquine or halofantrine have never been used intensively in Africa, principally because they are expensive. When policy changes lead to less use of oral quinine, BWF syndrome tends to disappear. Further similar reports from other areas in the African continent that would confirm our findings could have important implications on national policies for treating malaria in African children.

Acknowledgments

We thank Mr. Bernard and the entire staff of the pediatric ward of Kiremba Hospital.

References

(1.) Bruce-Chwatt LJ. Quinine and the mystery of blackwater fever. Acta Leiden. 1987;55:181-96.

(2.) White NJ. Malaria. In: Cook GC, Zumla AI, editors. Manson's tropical diseases. XXI ed. Philadelphia: W.B. Saunders; 2003. p. 1205-95.

(3.) Bruncel F, Gachot B, Wolff M, Regnier B, Danis M, Vachon F, et al. Resurgence of blackwater fever in long-term European expatriates in Africa: report of 21 cases and review. Clin Infect Dis. 2001;32: 1133-40.

(4.) Van den Ende J, Coppens G, Verstraeten T, Van Haeghenborgh T, Depraetere K, Van Gompel A, et al. Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health. 1998;3:632-9.

(5.) Bisoffi Z, Marocco S, Montero G, Marsiaj M. Acute intravascular haemolysis (blackwater fever) after malarial treatment. Trop Med Int Health. 1999;4:72-3.

(6.) Bruneel F, Gachot B, Wolff M, Bedos JR Regnier B, Danis M, et al. Blackwater fever. Presse Med. 2002;31:1329-34.

(7.) Rogier C, Imbert P, Tall A, Sokhna C, Spiegel A, Trape JF. Epidemiological and clinical aspects of blackwater fever among African children suffering frequent malaria attacks. Trans R Soc Trop Med Hyg. 2003;97:193-7.

(8.) Price R, Van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg. 1999;60:547-55.

(9.) World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94(Suppl1):S1-74.

(10.) Tran TH, Day NR Ly VC, Nguyen TH, Pham PL, Nguyen HP, et al. Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. Clin Infect Dis. 1996;23:1274-81.

(11.) Bonora S, De Rosa FG, Boffito M, Rossati A, Di Perri G. Rising temperature and the malaria epidemic in Burundi. Trends Parasitol. 2001;17:572-3.

(12.) Etchegorry MG, Matthys F, Galinski M, White NJ, Nosten F. Malaria epidemic in Burundi. Lancet. 2001;357:1046-7.

(13.) Ndayiragije A, Niyungeko D, Karenzo J, Niyungeko E, Barutwanayo M, Ciza A, et al. Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi. Trop Med Int Health. 2004;9:673-9.

(14.) Warrel DA. Clinical features of malaria, In: Warrel DA, Gilles HM, editors. Essential malariology. Fourth ed. London: Arnold; 2002. p. 191-205.

Federico Gobbi, * Sabrina Audagnotto, * Laura Trentini, * Innocent Nkurunziza, ([dagger]) Manuel Corachan, ([double dagger]) and Giovanni Di Perri *

* Clinica Universitaria Malattie Infettive, Turin, Italy; ([dagger]) Hopital de Kiremba, Ngozi, Burundi; and ([double dagger]) University Hospital, Barcelona, Spain

Dr. Gobbi is a specialist in infectious diseases at Turin University in Italy. Much of his research has been conducted in African countries (Burundi, Kenya, Democratic Republic of Congo, Uganda, Mozambique). His primary research interests are tropical diseases, in particular, malaria.

Address for correspondence: Federico Gobbi, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149, Torino, Italy; fax: 39-01-1439-3972: email: fedgobbi@tin.it

COPYRIGHT 2005 U.S. National Center for Infectious Diseases
COPYRIGHT 2005 Gale Group

Return to Mefloquine
Home Contact Resources Exchange Links ebay